101 – 200 of 535
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Alzheimer Disease : Standard of Diagnosis, Treatment, Care, and Prevention
(
- Contribution to journal › Article
-
Mark
Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE 4 carriers
(
- Contribution to journal › Article
-
Mark
Components of gait in people with and without mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
(
- Contribution to journal › Article
-
Mark
Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus
(
- Contribution to journal › Article
-
Mark
Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults : Effects of Alzheimer's Disease Pathology and Cognitive Decline
(
- Contribution to journal › Article
-
Mark
Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain : associations with pain severity and central sensitization
(
- Contribution to journal › Article
-
Mark
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article
-
Mark
Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217
(
- Contribution to journal › Article
-
Mark
The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders
(
- Contribution to journal › Article
-
Mark
Tau pathology mediates age effects on medial temporal lobe structure
(
- Contribution to journal › Article
-
Mark
Hippocampal subregional thinning related to tau pathology in early stages of Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Inter-modality assessment of medial temporal lobe atrophy in a non-demented population : application of a visual rating scale template across radiologists with varying clinical experience
(
- Contribution to journal › Article
-
Mark
A biomarker profile of elevated CSF p-tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
(
- Contribution to journal › Article
-
Mark
Blood-based biomarkers for Alzheimer's disease : towards clinical implementation
(
- Contribution to journal › Scientific review
-
Mark
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline
(
- Contribution to journal › Article
-
Mark
Age-related tau-PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease : a literature review
(
- Contribution to journal › Scientific review
-
Mark
Empirical pathological staging and subtyping of TDP-43 proteinopathies
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
(
- Contribution to journal › Article
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
Earlier Alzheimer's disease onset is associated with a shift of tau pathology towards brain hubs which facilitates tau spreading
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
CenTauRz : A standardized quantification of tau PET scans
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
(
- Contribution to journal › Article
-
Mark
Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading
(
- Contribution to journal › Article
-
Mark
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum
(
- Contribution to journal › Article
-
Mark
Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD) : A Report of an International Research Collaboration Network
(
- Contribution to journal › Scientific review
-
Mark
Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration
(
- Contribution to journal › Article
-
Mark
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers : Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
(
- Contribution to journal › Article
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
-
Mark
The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals
(
- Contribution to journal › Article
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings
(
- Contribution to journal › Article
- 2021
-
Mark
Biomarkers for neurodegenerative diseases
(
- Contribution to journal › Scientific review
-
Mark
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Management of Alzheimer's disease takes a leap forward
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Association between Apolipoprotein e ϵ2 vs ϵ4, Age, and β-Amyloid in Adults without Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
CSF Aβ42 and Aβ40 and their relation to brain soluble and insoluble Aβ in the 5xFAD mouse model of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
(
- Contribution to journal › Article
-
Mark
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Time between milestone events in the Alzheimer's disease amyloid cascade
(
- Contribution to journal › Article
-
Mark
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
(
- Contribution to journal › Article
-
Mark
Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment
(
- Contribution to journal › Article
-
Mark
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Neuroligin-1 in brain and CSF of neurodegenerative disorders : investigation for synaptic biomarkers
(
- Contribution to journal › Article
-
Mark
Genetic interaction study of Alzheimer's disease quantitative biomarkers : A polygenic risk score analysis and evaluation
(
- Contribution to journal › Article
-
Mark
Sex differences in off-target binding using tau positron emission tomography
(
- Contribution to journal › Article
-
Mark
The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people
(
- Contribution to journal › Article
-
Mark
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
(
- Contribution to journal › Article
-
Mark
Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study
(
- Contribution to journal › Article
-
Mark
Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age
(
- Contribution to journal › Article
-
Mark
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
(
- Contribution to journal › Article
-
Mark
Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
(
- Contribution to journal › Article
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
(
- Contribution to journal › Article
-
Mark
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
(
- Contribution to journal › Article
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article
-
Mark
Mapping genetic determinants of 184 circulating proteins in 26,494 individuals to connect proteins and diseases
2021)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
(
- Contribution to journal › Article
-
Mark
Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers : methodological update
(
- Contribution to journal › Article
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease : A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
(
- Contribution to journal › Article
-
Mark
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study
(
- Contribution to journal › Article
-
Mark
A multicentre validation study of the diagnostic value of plasma neurofilament light
(
- Contribution to journal › Article
-
Mark
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19
2021)(
- Working paper/Preprint › Preprint in preprint archive
- 2020
-
Mark
Cerebro-spinal fluid biomarker levels : phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
(
- Contribution to journal › Scientific review
-
Mark
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions : implications for cutoffs regarding cognitive impairment
(
- Contribution to journal › Article